ACADIA Pharmaceuticals (ACAD) Competitors $20.88 -0.07 (-0.33%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACAD vs. ITCI, GMAB, RDY, QGEN, MRNA, ASND, VTRS, BPMC, BBIO, and VRNAShould you be buying ACADIA Pharmaceuticals stock or one of its competitors? The main competitors of ACADIA Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. ACADIA Pharmaceuticals vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Intra-Cellular Therapies (NASDAQ:ITCI) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability. Do analysts rate ITCI or ACAD? Intra-Cellular Therapies presently has a consensus price target of $109.70, indicating a potential downside of 16.81%. ACADIA Pharmaceuticals has a consensus price target of $27.88, indicating a potential upside of 33.50%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17ACADIA Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.71 Does the media refer more to ITCI or ACAD? In the previous week, ACADIA Pharmaceuticals had 6 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 0 mentions for Intra-Cellular Therapies. ACADIA Pharmaceuticals' average media sentiment score of 0.70 beat Intra-Cellular Therapies' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral ACADIA Pharmaceuticals Positive Do institutionals & insiders believe in ITCI or ACAD? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, ITCI or ACAD? Intra-Cellular Therapies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Which has higher valuation & earnings, ITCI or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64ACADIA Pharmaceuticals$957.80M3.65$226.45M$1.3715.24 Is ITCI or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 22.97% compared to Intra-Cellular Therapies' net margin of -14.07%. ACADIA Pharmaceuticals' return on equity of 17.46% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% ACADIA Pharmaceuticals 22.97%17.46%10.75% SummaryACADIA Pharmaceuticals beats Intra-Cellular Therapies on 15 of the 17 factors compared between the two stocks. Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACAD vs. The Competition Export to ExcelMetricACADIA PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.49B$2.86B$5.45B$8.93BDividend YieldN/A2.44%5.22%4.01%P/E Ratio15.2420.4427.2420.06Price / Sales3.65283.79426.37117.54Price / Cash29.7241.7026.2128.59Price / Book4.757.397.925.56Net Income$226.45M-$55.04M$3.17B$248.56M7 Day Performance-3.20%3.43%4.40%7.56%1 Month Performance-5.00%0.16%2.64%8.54%1 Year Performance29.45%4.49%35.04%21.81% ACADIA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACADACADIA Pharmaceuticals4.6726 of 5 stars$20.88-0.3%$27.88+33.5%+29.9%$3.49B$957.80M15.24510ITCIIntra-Cellular Therapies0.9401 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8546 of 5 stars$20.66+0.8%$37.60+82.0%-20.1%$13.25B$3.12B11.742,682RDYDr. Reddy's Laboratories2.6856 of 5 stars$15.03-0.3%$16.95+12.8%-3.4%$12.55B$3.81B22.7727,811QGENQiagen3.855 of 5 stars$48.07+0.6%$49.40+2.8%+21.0%$10.69B$1.98B120.525,765Dividend AnnouncementMRNAModerna4.3693 of 5 stars$27.59+1.6%$46.61+68.9%-74.2%$10.67B$3.24B-3.165,800ASNDAscendis Pharma A/S3.4707 of 5 stars$172.60+0.2%$220.67+27.8%+28.2%$10.55B$393.54M-27.481,017Positive NewsVTRSViatris2.6575 of 5 stars$8.93-0.9%$10.40+16.5%-10.4%$10.48B$14.74B-2.8232,000BPMCBlueprint Medicines1.3772 of 5 stars$128.18+0.1%$128.06-0.1%+14.8%$8.28B$562.12M-51.89640BBIOBridgeBio Pharma4.668 of 5 stars$43.18-3.7%$58.85+36.3%+69.7%$8.20B$221.90M-12.23400High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.7655 of 5 stars$94.58+0.8%$101.10+6.9%+466.0%$8.05B$42.28M-47.2930Positive News Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Qiagen Alternatives Moderna Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACAD) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
